The 82nd Annual Meeting of the Japanese Cancer Association

Category

1-1
Activation and metabolism of carcinogens
1-2
Detection and assessment of carcinogens
1-3
DNA damage
1-4
Process of carcinogenesis
1-5
Nitric oxide/reactive oxygen
1-6
Genotoxins and nongenotoxins
1-7
Experimental cell culture systems
1-8
Radiation and electromagnetic wave carcinogenesi
1-9
Others
2-1
Gene-manipulated animal models
2-2
Animal model for carcinogenesis
2-3
Patient-derived experimental model
2-4
Others
3-1
EBV
3-2
HPV
3-3
HBV
3-4
HCV
3-5
HTLV-1
3-6
HHV-8
3-7
H.pylori
3-8
Other viruses/bacteria
3-9
Intestinal bacteria/microbiome
3-10
Inflammation and cancer
4-1
ras family genes
4-2
p53-related genes
4-3
Rb/p16-related genes
4-4
Wnt signaling-related genes
4-5
Chromosomal translocation-related genes
4-6
Other oncogenes/tumor-suppressor genes
4-7
Novel oncogenes/tumor-suppressor genes
5-1
Proliferation/differentiation
5-2
Signal transduction
5-3
Transcriptional regulation
5-4
Translational regulation
5-5
RNA engineering
5-6
ncRNA・microRNA
5-7
Single cell analysis
5-8
Others
6-1
Cell cycle/checkpoint
6-2
DNA replication
6-3
DNA repair
6-4
Genetic instability
7-1
Genomic analysis
7-2
Clonal evolution
7-3
Genomic medicine/precision medicine
7-4
NGS
7-5
Genome editing
7-6
Chromosomal translocation/gene rearrangement
7-7
Copy number analysis
7-8
Familial tumor and target genes
7-9
Carcinogenic sensitivity-related genes (SNPs)
7-10
Others
8-1
Cell death
8-2
Telomere/senescence/immnortalization
8-3
Others
9-1
DNA methylation
9-2
Histone modification
9-3
Chromatin structure
9-4
Others
10-1
Cell adhesion/invasion
10-2
Extracellular matrices and proteases
10-3
Metastasis-associated genes
10-4
Angiogenesis
10-5
Diagnosis of metastasis
10-6
Metastasis inhibition
10-7
Metastasis models
10-8
EMT (epithelial-mesenchymal transition)
10-9
Others
11-1
Cancer stem cells
11-2
Cell differentiation
11-3
Tumor heterogeneity
11-4
Cell-to-cell interaction/adhesion molecules
11-5
Cell lines
11-6
Organoid
11-7
Carbohydrate chains and glycosyltransferases
11-8
Extracellular vesicles/Exosome
11-9
Metabolism / Metabolome
11-10
Others
12-1
Innate immunity
12-2
Dendritic cells/antigen-presenting cells
12-3
Tumor antigens
12-4
Antitumor effector cells and their induction
12-5
Immune checkpoint inhibitors
12-6
Cell therapy
12-7
Antibody therapy
12-8
Other immunotherapies
12-9
Others
13-1
Growth- and differentiation-regulating factors
13-2
Growth factor receptors
13-3
Hormones
13-4
Cytokines
13-5
TGF-β/Smad
14-1
Gastric cancer
14-2
Esophageal cancer
14-3
Colorectal cancer
14-4
GIST
14-5
Liver cancer
14-6
Carcinoma of the biliary tract
14-7
Pancreatic cancer
14-8
Lung cancer
14-9
Breast cancer
14-10
Uterine cancer
14-11
Ovarian cancer
14-12
hematopoietic malignancy
14-13
Renal cell cancer
14-14
Bladder cancer
14-15
Prostatic cancer
14-16
Testicular cancer
14-17
Brain tumor
14-18
Primary bone tumor
14-19
Soft tissue sarcoma
14-20
Head and neck cancer
14-21
Endocrine cancer
14-22
Skin cancer
14-23
Childhood cancer/AYA
14-24
Other organs
15-1
Pathological diagnosis
15-2
Pathological analysis
15-3
Diagnostic imaging/cancer imaging
15-4
Diagnosis by tumor markers and biomarkers
15-5
Genomic diagnostics/Panel sequencing
15-6
Diagnosis by expression analysis (mRNA, protein)
15-7
Novel diagnostic technology
15-8
Liquid biopsy
15-9
Artificial intelligence based diagnostics
15-10
Others
16-1
Signal transduction inhibitors/kinase inhibitors
16-2
Angiogenesis inhibitors/antimetastatic drugs
16-3
Cell cycle inhibitors (CDK inhibitors etc.)
16-4
Epigenetic drugs
16-5
Proteolysis (proteasome inhibitors/PROTAC)
16-6
Engineered antibodies (ADC etc.)
16-7
Others
17-1
Natural anticancer compounds
17-2
Synthetic anticancer compounds
17-3
DNA-damaging drug
(Platinum compounds/Topoisomerase inhibitors etc.)
17-4
Antimetabolite
17-5
Antimicrotubular drugs（taxane/alkaloids etc.）
17-6
Anticancer drug resistance
17-7
Anticancer drug and cell death
17-8
Endocrine therapy
17-9
Differentiation-inducing therapy
17-10
Drug delivery system
17-11
Combinational therapy/adjuvant therapy
17-12
Others
18-1
Drug sensitivity/drug resistance-relating factors/gene expression analysis
18-2
Pharmacokinetics/pharmacodynamics (PK/PD)
18-3
Pharmacogenomics/toxicogenomics
(SNPs, transcriptome, proteome)
18-4
Sensitivity test
18-5
Clinical trial
18-6
Translational research
18-7
Biobank
19-1
Radiation and particle ray therapy
19-2
Radiation hazard/protection
19-3
Radiosensitivity
19-4
Efficacy enhancement
19-5
Hyperthermia
19-6
Others
20-1
Stem cells
20-2
Regenerative medicine
20-3
Cell therapy of allograft
20-4
Others
21-1
Generation and modification of vectors
21-2
Immunogenetic therapy
21-3
Oncogene/tumor-suppressor gene therapy
21-4
Suicide gene therapy
21-5
Nucleic acid therapeutics (including DDS)
21-6
Others
22-1
Psychooncology
22-2
Palliative treatment and care
22-3
Others
23-1
Mechanism of cacinogenesis inhibition
23-2
Synthetic compounds
23-3
Natural products
23-4
Dietary/alimentary factors
23-5
Others
24-1
Environmental factors (life habits etc.)/infectious exposure
24-2
Cancer prone syndromes/molecular epidemiology
24-3
Cohort study
24-4
Descriptive epidemiology/cancer registration
24-5
Cancer screening
24-6
Others
25-1
Bioinfomatics
25-2
Big Data/Real World Data analysis
25-3
Management and analysis of cancer patients' data
25-4
Mathmatical modeling and simulation
25-5
Real World Evidence
25-6
Others
26-1
Informed consent
26-2
Bioethics
26-3
Social movement against cancer
26-4
Smoking and drinking alcohol
26-5
Others